Mass Tort brief
Group Litigation Costs and Global Mass-Tort Liabilities
UK Supreme Court clarifies cost allocations while GSK and GLP-1 manufacturers navigate massive US personal injury exposure.
Mass Tort
US Zantac litigation continues to cast a shadow over GSK — state court trials and investor suits keep balance sheet risk front and center.
BackgroundGSK developed heartburn drug Zantac before selling distribution rights to other drugmakers. Plaintiffs allege long-term Zantac use caused cancer, while GSK maintains that scientific consensus shows no causal link between ranitidine and cancer.
- Delaware state courts allowed thousands of individual personal injury claims to proceed to jury trials, keeping legal defense costs and prospective damages elevated.
- The investor lawsuit alleges GSK leadership misled shareholders regarding the scope of prospective mass-tort liabilities, exposing top executives to securities fraud claims.
- Resolution of US bellwether trials remains critical for GSK's long-term balance sheet valuation and dividend distribution strategy, directly affecting UK pension fund investors.
Mass Tort
Supreme Court guidance lowers cost risks in UK class actions — clearer Group Litigation Order rules pave the way for bigger collective injury claims.
BackgroundCivil Procedure Rule Part 19.22 governs how High Court judges distribute legal cost burdens across claimants in group actions. Adverse cost risk has historically deterred UK litigation funders from backing large-scale environmental and product injury group lawsuits.
- The judgment clarifies rules for severing individual claims and structuring third-party funding arrangements in collective actions, reducing uncertainty for funders.
- High Court judges receive wider latitude to protect individual claimants from catastrophic adverse cost liability, preventing runaway legal bills from sinking group actions.
- Clearer cost allocation rules are expected to encourage UK class action law firms to bring expanded environmental and consumer injury claims before High Court judges.
Mass Tort
September scientific hearings will decide the fate of GLP-1 injury claims — US expert rulings will set the benchmark for global legal liabilities.
BackgroundPlaintiffs allege semaglutide and tirzepatide cause gastroparesis and optic neuropathy. Rule 702 hearings will determine whether plaintiff scientific expert testimony meets the legal standard for presentation before federal jury trials.
- Defense attorneys argue gastrointestinal side effects were adequately disclosed on drug safety labeling, seeking to dismiss expert testimony before trials reach juries.
- UK product liability law firms are watching the US MDL proceedings closely as NHS prescriptions for weight-loss injections expand rapidly across the country.
- Favorable scientific rulings for plaintiffs could accelerate pressure on pharmaceutical manufacturers to enter global settlement talks, establishing precedents for UK group litigation.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
